New drug combo shows promise for advanced throat cancer
NCT ID NCT05340270
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to chemotherapy before standard treatment can help people with advanced nasopharyngeal cancer live longer without the disease getting worse. About 150 adults with stage T4 or N2-3 cancer will receive either the drug combo or standard care. The main goal is to see if the combo delays cancer progression or death.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi, 530021, China
Conditions
Explore the condition pages connected to this study.